By Phil Boeyen, ShareChat Business News Editor
|
Thursday 21st February 2002 |
Text too small? |
For the six months ended December Ebos' sales hit $103.9 million compared with $50.4 million in the first half last year.
Net profit for the period was $2.28, a 16% increase on the previous year and earnings before interest and tax rose 36% to $4.75 million.
The company increased its holding in Health Support by 24% last July, meaning sales, assets and liabilities are now consolidated into group results.
"Earnings growth came from core business in both New Zealand and Australia. The Ebos business included three revenue streams - healthcare, consumer and scientific - which provided resilient in a demanding business climate," the company says.
Going forward Ebos says it is continuing to progress with growth initiatives including planned acquisitions and will divest a major part of its orthopaedic business as signalled in the last full year report.
Directors are forecasting a continuing positive revenue trend and pre-tax growth in core activities for the full year.
An interim dividend of 6.5 cents per share will be paid, the same as the previous year year.
No comments yet
Ebos still hungry for acquisitions after $1.1 bln Symbion deal, Waller says
Ebos meets prospectus forecast with 5.5 percent gain in FY profit
Ebos shareholders approve $1.1 billion purchase of Symbion
Ebos grabs scale with $1.1 bln purchase of Aussie pharma distributor Symbion
Ebos kicks tyres on potential acquisitions
Ebos lifts profit by 19%, targets growth in animal health
Ebos funding line smaller than previously flagged at $135 mln
Ebos Group
Ebos backs off British purchase, evaluates "significant" Australasian asset
Ebos reports higher profit, looks for acquisitions
